InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,728.80
(
0.00%
)
US TECH 100
19,510.00
(
0.07%
)
Dow Jones
42,052.19
(
0.00%
)
Brent Oil
74.85
(
1.05%
)
Bitcoin
68,868.96
(
0.19%
)
Post# of 253518
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120661
Boards Moderated 13
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 150407

Thursday, 10/11/2012 7:55:30 AM

Thursday, October 11, 2012 7:55:30 AM

Post# of 253518

Assuming thrice-weekly Copaxone entry in early 2014…

That may be optimistic. Before reviewing the NDA, the FDA may want to see the results of GALA’s open-label safety extension, which is slated to run until May 2014 (http://clinicaltrials.gov/ct2/show/NCT01067521 ). If so, market entry will likely be delayed until mid 2015.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up